Canakinumab(ILARIS) is a monoclonal antibody drug targeting IL-1β, used to treat a variety of inflammatory diseases. Patients need to purchase it through legal channels and understand the precautions in its use.
Where can I buy Canakinumab(ILARIS)?
Since Canakinumab has not yet been launched in China and there are no legal generic drugs, patients need to obtain genuine products through the following channels:
Purchase channels for original drugs from Novartis in Switzerland
The original drug Canakinumab is produced by Novartis in Switzerland, with a specification of 150mg/mL/vial. Patients can purchase it through regular cross-border medical service institutions, which usually provide drug authenticity verification services. Unopened Canakinumab needs to be refrigerated (2-8℃) and avoid freezing to ensure stable drug efficacy.
Key points for drug authenticity identification
Authentic Canakinumab is a sterile clear to milky white solution, with "Canakinumab" and production batch number marked on the package. Patients need to check the expiration date (24 months) and appearance characteristics, and avoid purchasing solutions with abnormal colors (such as obvious browning) or particles. It is recommended to choose an institution that provides official traceability certificates to ensure drug quality.
After understanding the purchase channels, we further explore the countermeasures for serious infections during medication.
Countermeasures for serious infections with canakinumab
Canakinumab may increase the risk of serious infections, and the following measures need to be taken to reduce the risk:
Infection monitoring and drug discontinuation treatment
If the patient has severe infection symptoms such as fever and persistent cough (such as sepsis or opportunistic infection), canakinumab should be discontinued immediately and medical treatment should be sought. The doctor may use antibiotics or antifungal drugs for treatment and re-evaluate the medication regimen. For suspected tuberculosis symptoms (such as persistent cough and weight loss), tuberculosis screening should be performed and appropriate treatment should be initiated.
Drug interactions and vaccination
Avoid combined use with TNF inhibitors (such as infliximab) because it may increase the risk of infection. Live vaccines (such as varicella vaccine) are prohibited during medication. It is recommended to complete inactivated vaccination (such as influenza vaccine, pneumococcal vaccine) before treatment.
After understanding the infection countermeasures, we further explore the pharmacokinetic properties of canakinumab.
Pharmacokinetics of Canakinumab
The pharmacokinetic properties of Canakinumab are of great reference value for the formulation of treatment plans. The following is key information:
Absorption and distribution
After Canakinumab is administered by subcutaneous injection, its absorption rate and extent are related to body weight. The typical characteristics of IgG antibodies make it widely distributed in the body, but it is difficult to penetrate the blood-brain barrier. The half-life is about 21-25 days, and the plasma clearance rate is low, which is suitable for long-term maintenance treatment.
Metabolism and excretion
The drug is mainly degraded by proteolytic enzymes rather than liver and kidney metabolism. Therefore, patients with hepatic and renal insufficiency do not need to adjust the dose, but need to monitor changes in drug exposure. Due to its long half-life, the drug effect may last for several weeks after treatment is interrupted.
Warm reminder: Before starting treatment, please communicate with the attending physician in detail about your personal medical history and drug contraindications. Purchase drugs through regular cross-border medical channels and keep the purchase receipt for authenticity verification. During treatment, regularly review blood routine, liver function and infection indicators, and promptly feedback any abnormal symptoms (such as persistent fever or redness and swelling at the injection site). Avoid receiving live vaccines while taking this medication, and inform your doctor of other medications you are taking to avoid the risk of interactions.
